VBI Vaccines Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $25.85 million
- Book Value:
- Revenue TTM:
- $1.82 million
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
VBI Vaccines Inc had its IPO on 1995-08-18 under the ticker symbol VBIV.
The company operates in the Healthcare sector and Biotechnology industry. VBI Vaccines Inc has a staff strength of 190 employees.
Shares of VBI Vaccines Inc opened at $1.2 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $1.08 - $1.2, and closed at $1.11.
This is a -1.77% slip from the previous day's closing price.
A total volume of 243,058 shares were traded at the close of the day’s session.
In the last one week, shares of VBI Vaccines Inc have slipped by -10.48%.
VBI Vaccines Inc's Key Ratios
VBI Vaccines Inc has a market cap of $25.85 million, indicating a price to book ratio of 1.5634 and a price to sales ratio of 139.5181.
In the last 12-months VBI Vaccines Inc’s revenue was $1.82 million with a gross profit of $-10194000 and an EBITDA of $-77414000. The EBITDA ratio measures VBI Vaccines Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, VBI Vaccines Inc’s operating margin was -4378.95% while its return on assets stood at -38.14% with a return of equity of -207.76%.
In Q2, VBI Vaccines Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 108.1%.
VBI Vaccines Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-13.72 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into VBI Vaccines Inc’s profitability.
VBI Vaccines Inc stock is trading at a EV to sales ratio of 114.2447 and a EV to EBITDA ratio of -0.9516. Its price to sales ratio in the trailing 12-months stood at 139.5181.
VBI Vaccines Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $88.32 million
- Total Liabilities
- $27.67 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
VBI Vaccines Inc ended 2023 with $88.32 million in total assets and $0 in total liabilities. Its intangible assets were valued at $88.32 million while shareholder equity stood at $8.74 million.
VBI Vaccines Inc ended 2023 with $0 in deferred long-term liabilities, $27.67 million in other current liabilities, 442322000.00 in common stock, $-561988000.00 in retained earnings and $2.18 million in goodwill. Its cash balance stood at $20.84 million and cash and short-term investments were $20.84 million. The company’s total short-term debt was $2,983,000 while long-term debt stood at $47.84 million.
VBI Vaccines Inc’s total current assets stands at $31.89 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $1.66 million compared to accounts payable of $7.35 million and inventory worth $6.86 million.
In 2023, VBI Vaccines Inc's operating cash flow was $0 while its capital expenditure stood at $50000.
Comparatively, VBI Vaccines Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
VBI Vaccines Inc stock is currently trading at $1.11 per share. It touched a 52-week high of $25.497 and a 52-week low of $25.497. Analysts tracking the stock have a 12-month average target price of $4.
Its 50-day moving average was $1.33 and 200-day moving average was $7.54 The short ratio stood at 0.31 indicating a short percent outstanding of 0%.
Around 952% of the company’s stock are held by insiders while 1362.1% are held by institutions.
Frequently Asked Questions About VBI Vaccines Inc
Similar Industry Stocks (Biotechnology)
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, an immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus. In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905. The company has collaboration and license agreements with Brii Biosciences Limited; GlaxoSmithKline Biologicals S.A.; and the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. It also has a collaboration with Coalition for Epidemic Preparedness Innovations to advance vaccine candidates against Covid-19 variants. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts.